References
- Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–668. doi: 10.1038/s41577-020-0306-5
- Jackson CM, Choi J, Lim M. Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat Immunol. 2019;20(9):1100–1109. doi: 10.1038/s41590-019-0433-y
- Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–1251. doi: 10.1093/neuonc/noab106
- Yu MW, Quail DF. Immunotherapy for Glioblastoma: Current progress and challenges. Front Immunol. 2021;12:676301. doi: 10.3389/fimmu.2021.676301
- Deckers J, Anbergen T, Hokke AM, et al. Engineering cytokine therapeutics. Nat Rev Bioeng. 2023;1(4):286–303. doi: 10.1038/s44222-023-00030-y
- Baldo BA. Side effects of cytokines approved for therapy. Drug Saf. 2014;37(11):921–943. doi: 10.1007/s40264-014-0226-z
- Riley RS, June CH, Langer R, et al. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18(3):175–196. doi: 10.1038/s41573-018-0006-z
- Berraondo P, Sanmamed MF, Ochoa MC, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2019;120(1):6–15. doi: 10.1038/s41416-018-0328-y
- Wang X-S, Zheng Z-S, Zheng M-F, et al. IL-2-loaded polypeptide nanoparticles for enhanced anti-cancer immunotherapy. Chin J Polym Sci. 2023;41(7):1059–1068. doi: 10.1007/s10118-023-2898-2
- Sousa F, Lee H, Almeida M, et al. Immunostimulatory nanoparticles delivering cytokines as a novel cancer nanoadjuvant to empower glioblastoma immunotherapy. Drug Deliv Transl Res. 2023. doi: 10.1007/s13346-023-01509-2
- Bhardwaj R, Suzuki A, Leland P, et al. Identification of a novel role of IL-13Rα2 in human glioblastoma multiforme: interleukin-13 mediates signal transduction through AP-1 pathway. J Transl Med. 2018;16(1):369. doi: 10.1186/s12967-018-1746-6
- Liang R, Wu C, Liu S, et al. Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers. Drug Deliv. 2022;29(1):1620–1630. doi: 10.1080/10717544.2022.2075986
- Gao H, Yang Z, Zhang S, et al. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci Rep. 2013;3(1):2534. doi: 10.1038/srep02534
- Zhang Y, Li N, Suh H, et al. Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity. Nat Commun. 2018;9(1):6. doi: 10.1038/s41467-017-02251-3
- Zhao P, Tian Y, Lu Y, et al. Biomimetic calcium carbonate nanoparticles delivered IL-12 mRNA for targeted glioblastoma sono-immunotherapy by ultrasound-induced necroptosis. J Nanobiotechnol. 2022;20(1): doi: 10.1186/s12951-022-01731-z
- Chiocca EA, Yu JS, Lukas RV, et al. Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: results of a phase 1 trial. Sci, Trans Med. 2019;11(505):eaaw5680. doi: 10.1126/scitranslmed.aaw5680
- Hotz C, Wagenaar TR, Gieseke F, et al. Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Sci Transl Med. 2021;13(610):eabc7804. doi: 10.1126/scitranslmed.abc7804
- Liu JQ, Zhang C, Zhang X, et al. Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy. J Control Release. 2022;345:306–313. doi: 10.1016/j.jconrel.2022.03.021
- Ghasemi A, Martinez-Usatorre A, Li L, et al. Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy. Nat Cancer. 2024;5(2):240–261. doi: 10.1038/s43018-023-00668-y
- Genoud V, Migliorini D. Novel pathophysiological insights into CAR-T cell associated neurotoxicity. Front Neurol. 2023;14:1108297. doi: 10.3389/fneur.2023.1108297